Becton Dickinson Posts 11-Percent Rise in Fiscal Q2 Revenue as R&D Spend Falls and Profit Jumps | GenomeWeb
NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal second-quarter revenues rose 11 percent as R&D spending decreased 32 percent and profit swelled 57 percent.
 
Total receipts for the three months ended March 31 increased to $1.6 billion from $1.4 billion year over year.
 
BD said revenues from its Diagnostics segment increased 11 percent to $473 million, while Biosciences revenue rose 13 percent to $258.5 million. Revenue from the Medical segment rose 10 percent to $844.1 million.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.